Clinical Trial Update: Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating LAF237 (vildagliptin) on glucagon secretion in patients with type 2 diabetes and in healthy subjects; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• LAF237

Snippet

Sponsor: Novartis | Conditions: Type-2 Diabetes, Healthy | Phase 3 | Status: COMPLETED